PHXM
PHAXIAM Therapeutics S.A.
NASDAQ: PHXM · HEALTHCARE · BIOTECHNOLOGY
$3.10
+0.00% today
Updated 2026-05-01
Market cap
$28.90M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-39.05
Dividend yield
—
52W range
$0 – $0
Volume
—
PHAXIAM Therapeutics S.A. (PHXM) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-191.00%
Operating margin
-3,232.00%
ROE
-38.60%
ROA
-15.00%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2010 | — | $-4.84M | — | — | — |
| 2011 | — | $-5.91M | — | — | — |
| 2012 | $1.84M | $-2.17M | -17.03% | -379.33% | -118.17% |
| 2013 | $1.80M | $-8.14M | -14.48% | -393.17% | -452.00% |
| 2014 | $4.37M | $-8.86M | — | -204.81% | -202.79% |
| 2015 | $10.78M | $-15.01M | — | -171.04% | -139.32% |
| 2016 | $19.72M | $-21.91M | — | -132.92% | -111.13% |
| 2017 | $3.36M | $-33.53M | -756.93% | -918.22% | -996.73% |
| 2018 | — | $-38.22M | — | — | — |
| 2019 | $5.28M | $-62.66M | 20.20% | 100.00% | -1,186.05% |
| 2020 | $0.00 | $-73.30M | — | — | — |
| 2021 | $0.00 | $-53.80M | — | — | — |
| 2022 | $0.00 | $-227000.00 | — | — | — |
| 2023 | — | $-23.49M | — | — | — |